[Featured Stock] TomoCube Leads Organoid and Glass Substrate Markets with Global Core Technology... Quadruple Expansion Investment

Tomocube is experiencing a sharp decline compared to its IPO price on the first day of listing on the KOSDAQ market.

As of 10:29 AM on the 7th, Tomocube is trading at 11,700 KRW, down 26.88% from its IPO price.

Tomocube is a cell imaging specialist company that owns the core technology of 'holotomography,' which allows real-time high-resolution observation of living cells without cell loss or deformation. From the 17th to the 23rd of last month, demand forecasting was conducted targeting institutional investors, and the IPO price was set at 16,000 KRW, exceeding the upper limit of the expected price range of 10,900 to 13,400 KRW.

Tomocube possesses the core technology of holotomography (HT). Holotomography is Tomocube's proprietary technology that enables real-time high-resolution observation of living cells or organoids without cell loss or deformation. Utilizing 3D imaging technology, it allows long-term observation of living three-dimensional cell structures and detects intracellular toxicity that was difficult to find with conventional microscopes. It can be applied to organoids, which are organ-like structures created by three-dimensional cell culture.

Tomocube independently develops all theories, optics, hardware, software, and AI technologies related to holotomography, maintaining a significant technological gap in the global market. Yonggeun Park, CEO of Tomocube, explained, "Tomocube leads the world in holotomography technology and maintains a technological gap of over five years compared to competitors. Tomocube is the only company with the capability to image three-dimensional samples such as organoids."

Seungyeon Han, a researcher at NH Investment & Securities, stated, "The global life science microscope market size reached 2 trillion KRW last year, mostly dominated by first to third-generation microscopes." He added, "Only Tomocube and Swiss company Nanolive possess fourth-generation HT technology."

He further explained, "Nanolive has technical limitations due to measurement height restrictions, making organoid analysis impossible. In contrast, Tomocube owns not only the low-cost HT-2H (laser) but also the HT-X1, which can measure organoids."

HT technology is useful for next-generation semiconductor glass substrate inspection. While conventional inspections measured the interior of industrial wafers by cutting, Tomocube's HT technology enables non-destructive 3D inspection of TGV (Through Glass Via) structures without damage, measuring the entire structure and inner wall roughness.

Jieun Kim, a researcher at DB Financial Investment, analyzed, "If non-destructive glass substrate inspection equipment using HT technology begins sales to domestic and international customers from next year, it will be advantageous for producing high-quality glass substrates, optimizing laser processes, and reducing defect rates compared to existing glass substrate inspection equipment." She added, "It is expected to significantly contribute to Tomocube's sales improvement. Currently, companies in partnership discussions include one in OLED, five related to glass substrates, two in AR glasses, and six in hybrid bonding."

Tomocube plans to expand its production facilities using funds raised through its IPO. Currently, the production facility can manufacture about 70 units annually based on exclusive production of the HT-X1 product. Anticipating a sharp increase in product sales after 2026, the company plans to establish facilities capable of producing 300 units annually by next year.